Topics

#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

11:10 EST 4 Dec 2019 | 2 Minute Medicine

1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence Rating Level: 1 (Excellent) Diffuse large B-cell lymphoma (DLBCL) is often curable, but a portion of patients are refractory to, or relapse after, treatment with the current standard of care (rituximab, cyclophosphamide, doxorubicin, vincristine, and […]
Source: 2 Minute Medicine

Original Article: #VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma"

Quick Search

Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...